

Contacts Media

Contact Investor Relations

+33 1 70 48 24 27

Amsterdam +31 20 721 4133 Dublin +353 87 361 2380 Milan +39 02 72 42 62 12

+353 87 361 2380 Lisbon +351 210 600 614 +39 02 72 42 62 12 Oslo +47 41 69 59 10

Brussels

Paris +33 1 70 48 24 45

# **AFYREN lists on Euronext Growth Paris**

- €66.5 million raised
- Market capitalisation of €206 million
- Greentech and French Tech 120 company
- Alumni of TechShare, Euronext's pre-IPO programme





**Paris – 01 October 2021** – Euronext today congratulates AFYREN, a Greentech sustainable chemistry company, on its listing on Euronext Growth (ticker code: ALAFY).

+32 2 620 15 50

AFYREN takes a low-carbon, circular-economy approach to offer its industrial customers innovative solutions to replace petroleum-based ingredients with products derived from non-food biomass. AFYREN's Initial Public Offering (IPO) aims to accelerate the industrialisation of its processes on a global scale in order to pursue its sustainable growth strategy, foster the circular economy and contribute to the emergence of a low-carbon world.

AFYREN was listed through the admission to trading on 1 October of the 25,762,024 shares making up its equity and of 8,286,359 new shares issued under a Global Offering<sup>1</sup>, after partial exercise of the extension option and before the potential exercise of the over-allotment option.

The admission and issue price of AFYREN shares was set at €8.02 per share. Market capitalisation was €206 million on the day of listing. The offering raised €66.5 million altogether.

**Nicolas Sordet, Chief Executive Officer and cofounder of AFYREN**, said: "We are very proud to join Euronext Paris, which has allowed us to broaden our shareholder base to include both individual shareholders and large institutional players. This listing is an important milestone for AFYREN's development in the production of natural and low-carbon products. The success of the operation also relied on the support of major investors, both new and historic, who showed their interest with subscription commitments of up to  $\mathfrak{C}35$  million even before the IPO was launched: Mirova, Bpifrance, Sofinnova Industrial Biotech and CACFdeveloppement."

Micheal Krel, Partner of the venture capital firm Sofinnova Partners and administrator of AFYREN: "We are proud to have accompanied AFYREN in its development, from when it was a young, innovative start-up to today as it enters its industrial phase, with additional resources to deploy its range of biosourced products across multiple continents."

<sup>&</sup>lt;sup>1</sup> The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.





**Caption**: Nicolas Sordet, Chief Executive Officer of AFYREN, and his team rang the bell in presence Guillaume Morelli, Director Listing SME France at Euronext, during a ceremony this morning to celebrate the Initial Public Offering of the company.

## **CONTACTS MEDIA**

Sarah Mound (Paris)	+33 1 70 48 24 45	parispressoffice@euronext.com
CONTACTS AFYREN		
<b>AFYREN - Finance Department</b> Maxime Cordonnier		investisseurs@afyren.com
Investors Relations NewCap Théo Martin	+ 33 1 44 71 94 94	afyren@newcap.eu
Media Relations NewCap Nicolas Merigeau	+ 33 1 44 71 94 98	afyren@newcap.eu
Alter'Com Conseil Estelle Monraisse	+ 33 6 60 41 81 52	estelle@altercom-conseil.fr

# **About AFYREN**

To meet manufacturers' growing need to combat global warming and reduce the use of petroleum derivatives in their production chain, AFYREN produces biomolecules derived from the recycling of non-food biomass, widely used in human and animal nutrition, flavours and fragrances, life sciences, materials sciences and lubricants sectors. This production of renewable carbon, which is resolutely part of a circular economy, is carried out using fermentative technologies patented worldwide, the result of 10 years of research. Founded in 2012 and managed by Nicolas Sordet and Jérémy Pessiot, AFYREN employs 33 people (as of year-end 2020) at its sites in Lyon, Clermont-Ferrand and Carling - Saint Avold. AFYREN is the winner of the 2030 Global Innovation Contest in the "Plant proteins and plant chemistry" category and was selected in the French Tech120 in January 2020 and 2021. In 2018, AFYREN embarked on the implementation of its industrial project with the creation of a joint venture with Bpifrance's SPI fund: AFYREN NEOXY. AFYREN NEOXY is dedicated to the first industrial production of AFYREN natural organic acids in the Grand Est region.

For more information: <u>afyren.com</u>

## **About Euronext**

Euronext is the leading pan-European market infrastructure, connecting local economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy,



the Netherlands, Norway and Portugal. With close to 1,900 listed issuers and around €6.4 trillion in market capitalisation as of end June 2021, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe's leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. Euronext provides custody and settlement services through central securities depositories in Denmark, Italy, Norway and Portugal.

For the latest news, go to euronext.com or follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

#### Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.

© 2021, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: www.euronext.com/privacy-policy. In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: www.euronext.com/data\_subjects\_rights\_request\_information. To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com.

